Stay updated with breaking news from Kellsie Hope Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NAUVOO, Ill. – To celebrate Catholic Schools Week this year, which was Jan. 28 through Feb. 2, Sts. Peter & Paul School in Nauvoo, Ill., has been raising money for
Starving cancer cells of the energy they need to grow could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, according to a new study. Studying human cancer cells and mice, researchers report that a two-drug combination targeting a tumor’s energy sources could prove as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer. Osteosarcoma is the most common tumor of the bone in adults and children. It accounts for about 4% of all pediatric cancers and m...
Two drugs targeting cancer cells’ energy source potentially could replace toxic chemo in osteosarcoma January 26, 2021 SHARE A new study from Washington University School of Medicine in St. Louis suggests that a two-drug combination targeting a tumor’s energy sources could be as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer. Shown is a cross section of osteosarcoma. (Image: Richa Rathore) An innovative approach to treating bone tumors — starving cancer cells of the energy they need to grow ...
E-Mail IMAGE: A new study from Washington University School of Medicine in St. Louis suggests that a two-drug combination targeting a tumor's energy sources could be as effective and less toxic than... view more Credit: RICHA RATHORE An innovative approach to treating bone tumors - starving cancer cells of the energy they need to grow - could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, suggests a new study from Washington University School of Medicine in St. Louis. Studying human cancer cells and mice, the researcher...